T-1194
0T-1194 is a synthetic steroid that was developed for potential use in the treatment of hypertension and heart failure. It is a mineralocorticoid receptor antagonist (MRA) that has been studied in preclinical trials.
History[edit]
T-1194 was first synthesized in the late 20th century as part of a series of compounds designed to block the mineralocorticoid receptor. This receptor is involved in the regulation of blood pressure and fluid balance, and its overactivation can lead to hypertension and heart failure.
Mechanism of Action[edit]
T-1194 acts by binding to the mineralocorticoid receptor and preventing it from activating. This reduces the effects of aldosterone, a hormone that increases blood pressure and fluid retention. By blocking the action of aldosterone, T-1194 can help to lower blood pressure and reduce the symptoms of heart failure.
Clinical Trials[edit]
Preclinical trials of T-1194 have shown promising results, with the compound demonstrating a strong ability to block the mineralocorticoid receptor and reduce blood pressure in animal models. However, further research is needed to determine the safety and efficacy of T-1194 in humans.
Potential Applications[edit]
If proven safe and effective in clinical trials, T-1194 could potentially be used in the treatment of conditions such as hypertension and heart failure. It may also have potential applications in the treatment of other conditions related to overactivation of the mineralocorticoid receptor, such as kidney disease and liver disease.
See Also[edit]
References[edit]
